Hereditary Angioedema - Kalbitor
Customize your policy alerts
Sign up for Cigna Policy IP0336 alerts
Get alerted when Policy IP0336 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Kalbitor (ecallantide) subcutaneous injection for acute attacks of hereditary angioedema due to C1-inhibitor deficiency.
Coverage was revised to specify hereditary angioedema due to C1-inhibitor deficiency for acute attacks.
Low functional C1-INH protein and lower-than-normal baseline serum C4 are now required for diagnostic confirmation.
The requirement for a confirmed pathogenic variant in specified genes was removed.
Coverage criteria now require confirmed HAE type I or type II and expressly exclude HAE with normal C1-INH.
The requirement for low baseline C1-inhibitor antigenic levels was removed.
The requirement prohibiting concomitant use with other FDA-approved acute HAE treatments was removed.
A specialist requirement was added and clarified.
Criteria for previous Kalbitor treatment were added.
Preferred-product criteria were revised by plan type.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.